In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated by Clinical Laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015

The prevalence of pathogenic multidrug-resistant (MDR) and carbapenem-nonsusceptible Gram-negative bacilli (GNB) is increasing in frequency worldwide [1 –3]. Therapeutic options available to treat patients with MDR and carbapenem-resistant GNB infections are currently limited [4, 5]. New β-lactam/β-lactamase inhibitor combinations have recently been approved (ceftazidime-avibactam, ceftolozane-tazobactam, meropenem-vaborbactam), however, none of these agents is active against isolates of GNB carrying Ambler class B metallo-β-lactamases and their activity against Class D (OXA) β-lactamases may be limited [1, 2, 6–8].
Source: International Journal of Antimicrobial Agents - Category: Drugs & Pharmacology Authors: Source Type: research